Effects of intracoronary diltiazem on no-reflow phenomenon after emergent percutaneous coronary intervention in patients with acute myocardial infarction.
- Author:
Zhao-fen ZHENG
1
;
Xiao-qun PU
;
Tian-lun YANG
;
Chuan-chang LI
;
Dao-di PENG
;
Zai-xin YU
;
Long MO
;
Xiao-bin CHEN
Author Information
1. Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Angioplasty, Balloon, Coronary;
Diltiazem;
administration & dosage;
therapeutic use;
Female;
Humans;
Male;
Middle Aged;
Myocardial Infarction;
therapy;
No-Reflow Phenomenon;
drug therapy;
Stents;
Treatment Outcome
- From:
Journal of Central South University(Medical Sciences)
2006;31(6):917-920
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the effects of intracoronary diltiazem on no-reflow phenomenon of infarct-related artery (IRA) after emergent percutaneous transluminal coronary angioplasty or/and intracoronary stenting (PTCA/Stenting) in the patients with acute myocardial infarction (AMI).
METHODS:We studied 34 AMI patients with no-reflow phenomenon of IRA after emergent PTCA/Stenting between January 1999 and August 2005. Urokinase-treated group (n=16) was given intracoronary urokinase 30,0000 - 50,0000 units within 15 - 30 minutes between January 1999 and April 2002 while diltiazem-treated group (n=18) was given intracoronary diltiazem 0.5 - 2 mg within 10 - 30 minutes between May 2002 and August 2005. Fifteen minutes later, coronary arteriography (CAG) was performed and the thrombolysis in myocardial infarction (TIMI) flow grade was measured.
RESULTS:No apparent change of TIMI flow grade was found between pre-administration and post-administration of intracoronary urokinase, but TIMI flow grade was significantly improved after intracoronary diltiazem (P<0.01). TIMI flow grade of diltiazem-treated group was significantly higher than that of urokinase-treated group after the administration (P<0.05). The percentage of the patients who reached TIMI flow grade 3 after the intracoronary administration was higher in the diltiazem-treated group than that in the urokinase-treated group (P<0.01).
CONCLUSION:The intracoronary administration of diltiazem 0.5~2mg can effectively improve the no-reflow phenomenon after emergent PTCA/Stenting in patients with AMI.
